Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells

International Journal of Molecular Medicine

Volumn 19, Issue 2, 2007, Pages 301-308

  Ueda, Tami ^a   Takai, Noriyuki ^a   Nishida, Masakazu ^a   Nasu, Kaei ^a   Narahara, Hisashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Apicidin; Apoptosis; Cell cycle; Endometrial cancer; Ovarian cancer

Indexed keywords

APICIDIN; CELL CYCLE PROTEIN; CYCLOPEPTIDE; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE;

ACETYLATION; ARTICLE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENDOMETRIUM TUMOR; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ACETYLATION; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HISTONES; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MOLECULAR STRUCTURE; OVARIAN NEOPLASMS; PEPTIDES, CYCLIC;

EID: 33847796188     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.19.2.301     Document Type: Article

References (41)

1. Covens A, Brunetto VL, Markman M, Orr JW Jr, Lentz SS and Benda J: Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 89: 470-474, 2003.
2. Ball HG, Blessing JA, Lentz SS and Mutch DG: A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62: 278-291, 1996.
3. Thigpen T, Brady MF, Alvarez D, et al: Oral medroxy-progesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group (GOG) study. J Clin Oncol 17: 1736-1744, 1999.
4. Felsenfeld G: Chromatin as an essential part of the transcriptional mechanism. Nature 355: 219-224, 1992.
5. Wolffe AP: Transcription: in tune with the histones. Cell 77: 13-16, 1994.
6. Strahl BD and Allis CD: The language of covalent histone modifications. Nature 403: 41-45, 2000.
7. Darkin-Rattray SJ, Gurnett AM, Myers RW, et al: Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci USA 93: 13143-13147, 1996.
8. WAF1/Cip1 and gelsolin. Cancer Res 60: 6068-6074, 2000.
9. Kijima M, Yoshida M, Sugita K, Horinouchi S and Beppu T: Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268: 22429-22435, 1993.
10. Koyama Y, Adachi M, Sekiya M, Takekawa M and Imai K: Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood 96: 1490-1495, 2000.
11. Gu W and Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606, 1997.
12. Zhang W and Bieker JJ: Acetylation and modulation of erythroid Kuppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc Natl Acad Sci USA 95: 9855-9860, 1998.
13. Pazin MJ and Kadonaga JT: What's up and down with histone deacetylation and transcription? Cell 89: 325-328, 1997.
14. Wolffe AP: Transcriptional control. Sinful repression. Nature 387: 16-17, 1997.
15. Ogryzko VV, Kotani T, Zhang X, et al: Histone-like TAFs within the PCAF histone acetylase complex. Cell 94: 35-44, 1998. (Pubitemid 28347467)
16. Grant PA, Schieltz D, Pray-Grant MG, et al: A subset of TAF(II)s are integral components of the SAGA complex required for nucleosome acetylation and transcriptional stimulation. Cell 94: 45-53, 1998.
17. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S and Beppu T: Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 214: 189-197, 1994.
18. Darkin-Rattray SJ, Gurnett AM, Myers RW, et al: Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci USA 93: 13143-13147, 1996.
19. Kim MS, Son MW, Kim WB, Park YI and Moon A: Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett 157: 23-30, 2000.
20. Kim JS, Lee S, Lee T, Lee YW and Trepel JB: Transcriptional activation of p21WAF1/CIP1 by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 281: 866-871, 2001.
21. Takai N, Desmond JC, Kumagai T, et al: Histone deacetylase inhibitors have a profound anti-growth activity in endometrial cancer cells. Clin Cancer Res 10: 1141-1149, 2004.
22. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I and Koeffler HP: Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101: 2760-2770, 2004.
23. Bannister AJ and Kouzarides T: The CBP co-activator is a histone acetyltransferase. Nature 382: 641-643, 1996.
24. Ogryzko VV, Schiltz RL, Russanova V, Howard BH and Nakatani Y: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959, 1996.
25. Mizzen CA, Yang XJ, Kokubo T, et al: The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell 87: 1261-1270, 1996.
26. Nagy L, Kao HY, Chakravarti D, et al: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89: 373-380, 1997.
27. Hassig CA, Fleischer TC, Billin AN, Schreiber SL and Ayer DE: Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89: 341-347, 1997.
28. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E and Eisenman RN: Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89: 349-356, 1997.
29. Johnson DG and Walker CL: Cyclins and cell cycle check-points. Annu Rev Pharmacol Toxicol 39: 295-312, 1999.
30. Cairns P, Polascik TJ, Eby Y, et al: Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet 11: 210-212, 1995.
31. Nakagawa K, Conrad NK, Williams JP, Johnson BE and Kelly MJ: Mechanism of inactivation of CDKN2 and MTS2 in non-small-cell lung cancer and association with advanced stage. Oncogene 11: 1843-1851, 1995.
32. Kinoshita I, Dosaka-Akita H, Mishina T, et al: Altered p16 and retinoblastoma protein status in non-small-cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 56: 5557-5562, 1996.
33. Barbieri F, Cagnoli M, Ragni N, Pedulla F, Fogalia G and Alama A: Expression of cyclin D1 correlates with malignancy in human ovarian tumors. Br J Cancer 75: 1263-1268, 1997. (Pubitemid 27179814)
34. INK4A in primary gynecologic malignancy. Cancer Lett 136: 231-235, 1999.
35. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455, 1991.
36. Graff JR, Herman JG, Lapidus RL, et al: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55: 5195-5199, 1995.
37. Nass SJ, Hermann JG, Gabrielson E, Iversen PW, Davidson NE and Graff JR: Aberrant methylation of the estrogen receptor E-cadherin 5′ CpG island increases with malignant progression in human breast cancer. Cancer Res 15: 4346-4348, 2000.
38. Saito T, Mishimura M, Yamasaki H and Kudo R: Hypermethylation in promoter region of E-cadherin gene is associated with tumor differentiation and myometrial invasion in endometrial carcinoma. Cancer 15: 1002-1009, 2003.
39. Cameron EE, Backman KE, Myohanen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107, 1999.
40. Sherr CJ: G1 phase progression: cyclin on cue. Cell 79: 551-555, 1994.
41. Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T and Kuramoto H: Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol 128: 307-312, 2002.